Suchergebnisse - "Cahn, Avivit"

PubPharm (23)

1

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose : Post Hoc Analyses From DECLARE-TIMI 58

enthalten in: Diabetes care | 2023

von Pollack, R. | Raz, I. | Wiviott, S. | +13

2

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes : Post Hoc Analyses From the DECLARE-TIMI 58 Trial

enthalten in: Diabetes care | 2022

von Mosenzon, O. | Raz, I. | Wiviott, S. | +18

3

Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes : A Prespecified Secondary Analysis of a Randomized Clinical Trial

enthalten in: JAMA cardiology | 2022

von Oyama, K. | Raz, I. | Cahn, A. | +9

4

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

enthalten in: European heart journal | 2022

von Oyama, K. | Raz, I. | Cahn, A. | +14

CommentIn: Eur Heart J. 2021 Oct 07;:. - PMID 34618015

5

Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure : Observations From DECLARE-TIMI 58 Trial

enthalten in: Circulation | 2022

von Furtado, R. | Raz, I. | Goodrich, E. | +17

6

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

enthalten in: Diabetes care | 2021

von Mosenzon, O. | Wiviott, S. | Heerspink, H. | +18

7

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes : A Prespecified Secondary Analysis of a Randomized Clinical Trial

enthalten in: JAMA cardiology | 2021

von Zelniker, T. | Raz, I. | Mosenzon, O. | +13

8

The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus

enthalten in: Diabetologia | 2021

von O'Donoghue, M. | Kato, E. | Mosenzon, O. | +15

9

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort : Analyses From DECLARE-TIMI 58

enthalten in: Diabetes care | 2021

von Cahn, A. | Raz, I. | Leiter, L. | +12

10

The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus : An economic evaluation using data from the DECLARE-TIMI 58 trial

enthalten in: Diabetes, obesity & metabolism | 2021

von McEwan, P. | Morgan, A. | Boyce, R. | +8